Clinical trials
Observational Insulin Resistance trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Hospital, Lille | 2 |
| AstraZeneca | 1 |
| Central Hospital, Nancy, France | 1 |
| Centre Hospitalier Universitaire de Besancon | 1 |
| Centre Hospitalier Universitaire de Nīmes | 1 |
| Fondation Lenval | 1 |
| French Society for Intensive Care | 1 |
| Groupe Hospitalier Pitie-Salpetriere | 1 |
| Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement | 1 |
| Prof. Valérie Mc Lin | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Insulin Resistance | 14 |
| Diabetes Mellitus, Type 2 | 5 |
| Diabetes Mellitus, Type 1 | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Obesity | 2 |
| Congenital Portosystemic Shunt | 1 |
| Diabetes Mellitus | 1 |
| Fatty Liver | 1 |
| Feeding and Eating Disorders | 1 |
| Hepatic Encephalopathy | 1 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.